Citing a crowded market of innovative meds, Janssen has canned work on its hep C cocktail program with partners Medivir and Achillion.

Monday's prescription for your news of note

As CAR-T and T-cell therapies continue to make headlines, GSK has taken up the option for Adaptimmune’s T-cell therapy.

Wednesday's shot of your news of note.

With CAR-T therapies now reaching the market, Japanese drugmaker Takeda has made a play to grab a slice of the pie via a deal with biotech startup Noile-Immune.

Janssen is ending a license deal with MacroGenics for duvortuxizumab, a CD19- and CD3-targeting drug for B-cell malignancies.

Flagship Pioneering’s quiet oncology upstart Torque Therapeutics has filed a $21 million raise as it lands in Kendall Square.

The deal gives Jazz an option to pick up worldwide rights to two hematology antibody-drug conjugates and a third as-yet-unidentified program.  

After just two years, Five Prime Therapeutics has ducked out of an immuno-oncology collaboration with InhibRx that on signing had a value of more than $460…